High-density lipoprotein (HDL) functionality has been reported to be associated with coronary artery disease (CAD). However, little is known about the impact of HDL on atherosclerosis. Thirty-eight type 2 diabetic patients CAD who underwent percutaneous intervention were examined. Coronary atheroma burden and plaque composition culprit lesions assessed using conventional gray-scale integrated b...

Background: Abnormal lipid metabolism predisposes to cardiovascular disease. However, dyslipidemia is often asymptomatic leading its underdiagnosis. Therefore, it of utmost importance identify biomarkers that reflect an abnormal profile and trigger the specific investigation metabolism. The platelet–monocyte ratio (PMR) a severely understudied index whose association with disturbed markers rema...

OBJECTIVE We investigated relationships between statin and niacin/statin combination therapy and the concentration of high-density lipoprotein particles (HDL-P) and cholesterol efflux capacity, 2 HDL metrics that might better assess cardiovascular disease risk than HDL-cholesterol (HDL-C) levels. APPROACH In the Carotid Plaque Composition Study, 126 subjects with a history of cardiovascular d...

A high resolution electrophoretic method has been developed to separate plasma high density lipoprotein (HDL) particles by size using 4-30% polyacrylamide agarose (PAA) gradient gels, Sudan black B staining, and laser densitometry. Fourteen distinct HDL bands were observed with HDL-1 being designated as the largest particle and HDL-14 as the smallest particle. HDL-1 was similar in size to ferri...

Evidence indicates that the high density lipoprotein (HDL) subfraction containing apolipoprotein A-I without apolipoprotein AII (LP-AI) is more antiatherogenic than HDL particles containing apolipoprotein A-I and apolipoprotein A-II (LP-AI+AII). This study examined the effect of extended-release niacin (niacin-ER) and gemfibrozil on LP-AI and LP-AI+AII particles in patients with low levels of H...